Home/Filings/4/0000899243-20-006973
4//SEC Filing

SCHIERMEIER ANDREW 4

Accession 0000899243-20-006973

CIK 0001652130other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 5:27 PM ET

Size

8.9 KB

Accession

0000899243-20-006973

Insider Transaction Report

Form 4
Period: 2020-01-03
SCHIERMEIER ANDREW
EVP, Dev and Corp Strategy
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-01-03+15,00015,000 total
    Exercise: $13.48From: 2020-01-03Exp: 2027-01-02Common Stock (15,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2020-03-02+135,000135,000 total
    Exercise: $13.40Exp: 2030-03-01Common Stock (135,000 underlying)
Holdings
  • Common Stock

    10,316
Footnotes (3)
  • [F1]This amount includes 1,672 shares acquired under the NTLA Employee Stock Purchase Plan (912 shares purchased on 6/30/2019 and 760 shares purchased on 12/31/2019).
  • [F2]On January 3, 2017, the reporting person was granted an option to purchase 15,000 shares of common stock. The option vested based on the satisfaction of certain performance criteria. The performance criteria was met, resulting in the vesting of option as to 15,000 shares.
  • [F3]This option was granted on March 2, 2020 with respect to 135,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1
  • filerCIK 0001738456

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 5:27 PM ET
Size
8.9 KB